Skip to Main Content
Try STAT+ TODAY
Trending:
Health
STAT+
Biotech
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

STAT+ Conversations: An update from STAT’s Pharmalot

  • Megan Thielking

By Megan Thielking May 4, 2021

Reprints

Editor’s note: A recording of the conversation is embedded below.

Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week STAT news editor Megan Thielking will be joined by STAT’s Pharmalot columnist and senior writer, Ed Silverman for an update from STAT’s Pharmalot campus. They will be discussing topics relating to global access to Covid-19 vaccines, pharma patent fights, the latest on the drug pricing debate, and of course be taking your questions live.

advertisement

 

Featured speakers:

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Megan Thielking

Megan Thielking

Senior News Editor

Tags

Insurance alone didn’t guarantee adherence to Ozempic, study finds
Insurance alone didn’t guarantee adherence to Ozempic, study finds
Coherus works with Mark Cuban to sell biosimilar Humira…
Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts
Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves…
Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves second RSV vaccine
Coherus works with Mark Cuban to sell biosimilar Humira…
Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts
Republicans want to crack down on pricey health regulations,…
Republicans want to crack down on pricey health regulations, but there are major loopholes
CVS warns PBM reforms ‘could lead to higher costs’
CVS warns PBM reforms ‘could lead to higher costs’

Recommended Stories